SCHEMBL3040422

SCHEMBL3040422

Cc1cnc(NC(=O)C(=O)O)s1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.57
NPC1 O15118 8/20 0.57
SMN1; SMN2 Q16637 7/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
PKM P14618 4/20 0.54
TP53 P04637 1/20 0.54
MAPT P10636 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
LMNA P02545 1/20 0.52
HTT P42858 1/20 0.52
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3794688 0.86 RAB9A (0.62) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL2175131 0.81 RAB9A (0.60) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL6474925 0.79 RAB9A (0.58) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL11224076 0.78 ALDH1A1 (0.61) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL15943684 0.78 RAB9A (0.57) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL13401787 0.78 RAB9A (0.60) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL11224487 0.77 CCNE1 (0.61) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL6361249 0.76 SMN1; SMN2 (0.61) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL13156686 0.76 CCNE1 (0.68) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL2880446 0.76 RAB9A (0.56) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100129366-A1 THIAZOLE INHIBITORS OF CYCLOOXYGENASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-27 US disclosed
US-4321372-A Antiulcer thiazol-2-ylcarbamoyl-carboxylic acids, esters and amides PFIZER INC. (US) 1982-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100129366-A1 THIAZOLE INHIBITORS OF CYCLOOXYGENASE PTGES2, PTGES, PTGES3 RAB9A 4832/4885NPC1 3568/4885SMN1; SMN2 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.